Barrie J. Carter has been named executive vice president anddirector of R&D at Targeted Genetics Corp. of Seattle. Carter waschief of the laboratory of molecular and cellular biology at theNational Institute of Diabetes, Digestive and Kidney Diseases.Targeted Genetics is developing gene therapy treatments.
Peter E. Jansen has been named vice president and chieffinancial officer of Genelabs Technologies Inc. of Redwood City,Calif. He was senior assistant treasurer and internationaltreasurer at Abbott Laboratories. Genelabs (NASDAQ:GNLB) isdeveloping products for diagnosing and treating viral diseasesand cancer.
Affymax Research Institute has named Eric M. Gordon vicepresident of research and director of chemistry. He wasdirector of medicinal chemistry for the Bristol-Myers SquibbPharmaceutical Institute. Palo Alto, Calif.-based Affymax is theresearch arm of Affymax N.V. of Amsterdam (NASDAQ:AFMXF),a drug discovery company.
North American Biologicals Inc. has named Stephen W. Westonvice president of plasma operations. He was vice president forfinance at ConPharma Home HealthCare. William W. Watkins,formerly a marketing manager in international businessdevelopment at Baxter Healthcare Corp., has been nameddirector of sales and marketing. And William E. Vandervalk,formerly human resources manager for Key Pharmaceuticals,was named director of human resources. North AmericanBiologicals (NASDAQ:NABI) of Miami is a provider of humanblood plasma elements.
Elizabeth Lane, director of pharmacokinetics and regulatoryaffairs at PharmaKinetics Laboratories Inc., has been named avice president. She will also serve as acting chief scientificofficer. Current CSO Lawrence J. Lesko has resigned as vicepresident, chief scientific officer and corporate secretary totake a position with the Center for Drug Evaluation andResearch of the FDA. Also, Joseph Goebels has been nameddirector of human resources and Richard Kline has been namedsection director in the analytical laboratory division.PharmaKinetics (NASDAQ:PKLBQ) provides services tocompanies seeking new drug approvals in the United Statesand Europe.
Bert Vandervelde has been named manager of CellPro EuropeN.V., the newly incorporated subsidiary of CellPro Inc. ofBothell, Wash. He was in charge of automation marketing atBaxter, Fenwal Europe. CellPro (NASDAQ:CPRO) focuses on cellselection systems.
(c) 1997 American Health Consultants. All rights reserved.